| Literature DB >> 34442276 |
Salum Azizi1,2, Janneke Snetselaar1,2,3,4, Alexandra Wright4, Johnson Matowo1,2, Boniface Shirima1,2, Robert Kaaya1,2, Rashid Athumani1,2, Filemoni Tenu1,2, Natacha Protopopoff1,2,4, Matthew Kirby1,2,4.
Abstract
BACKGROUND: The emergence and spread of insecticide resistance in malaria vectors to major classes of insecticides call for urgent innovation and application of insecticides with novel modes of action. When evaluating new insecticides for public health, potential candidates need to be screened against both susceptible and resistant mosquitoes to determine efficacy and to identify potential cross-resistance to insecticides currently used for mosquito control. The challenges and lessons learned from establishing, maintaining, and authenticating the pyrethroid-resistant An. gambiae s.s. Muleba-Kis strain at the KCMUCo-PAMVERC Test Facility are described in this paper.Entities:
Keywords: insecticide selection; laboratory screening; out-crossing; strain authentication
Year: 2021 PMID: 34442276 PMCID: PMC8396659 DOI: 10.3390/insects12080710
Source DB: PubMed Journal: Insects ISSN: 2075-4450 Impact factor: 2.769
Figure 1Map showing mosquito collection site in north-western Tanzania.
Figure 2The timeline for activities, indicating wild mosquito collection, insectary colonization, out-crossing, selection, and strain characterization across An. gambiae Muleba-Kis generations.
Figure 3Image of wing aligned on a micrometer indicating the ocular gradations which correspond to the distance on the stage micrometer. Number 1–5 indicates the wing veins, where vein 3 is used for measuring the distance from the alula to the wing fringe (wing length). This photo was copied from PAMVERC Test Facility SOP with permission, originally taken and donated by MK (co-author).
Figure 4Dynamics of mortality rates of the selected larvae when different pyrethroids were used for the selection at different generations (G).
Figure 5WHO susceptibility profiling of adult An. gambiae Muleba-Kisumu across generations. Mortality less than 90% indicates resistance, WHO (51). G = Generation.
Figure 6The knockdown and mortality rates of An. gambiae Kisumu and An. gambiae Muleba-Kis with and without PBO pre-exposure. Error bars are equivalent to 95% confidence intervals. PRM = Permethrin, PBO = Piperonyl butoxide.
Molecular assays for Muleba-Kis strain over generations.
| Generation | Number of Samples | Molecular Assay | ||||||
|---|---|---|---|---|---|---|---|---|
| Species | ||||||||
| %Ar | %Ga | %RRe | %RSe | %SSe | %RRe | %SSe | ||
| G43 | 37 | 0 | 100 | 30 | 27 | 43 | 0 | 100 |
| G99 | 57 | 0 | 100 | 100 | 0 | 0 | 0 | 100 |
| G131 | 50 | 0 | 100 | 100 | 0 | 0 | 0 | 100 |
| G150 | 84 | 0 | 100 | 100 | 0 | 0 | N | N |
| G162 | 100 | 0 | 100 | 100 | 0 | 0 | N | N |
| G168 | 84 | 0 | 100 | 100 | 0 | 0 | N | N |
| G178 | 84 | 0 | 100 | 100 | 0 | 0 | N | N |
| G188 | 84 | 0 | 100 | 100 | 0 | 0 | N | N |
| G190 | 84 | 0 | 100 | 100 | 0 | 0 | 0 | 100 |
| G198 | 88 | 0 | 100 | 100 | 0 | 0 | N | N |
| G204 | 88 | 0 | 100 | 100 | 0 | 0 | N | N |
Note: Ar = An. arabiensis, Ga = An. gambiae ss, Ace-1 = insensitive acetylcholinesterase, RRe = homozygous mutant, RSe = heterozygous mutant, SSe = homozygous susceptible. When an assay was not done it is coded as N.
Figure 7Mortality percentage of An. gambiae Kisumu and An. gambiae Muleba-Kis to varying concentrations of α-cypermethrin in CDC bottle bioassay.
Dynamics in mosquito wing length across years 2016, 2017, 2019, and 2020.
| Year | Samples (N) | Mean Wing Length | 95% CI | |
|---|---|---|---|---|
| 2016 | 50 | 2.9504 | 2.8995-3.0013 | 0.6592 |
| 2017 | 150 | 2.9362 | 2.9035–2.9689 | |
| 2017 | 150 | 2.9362 | 2.9035–2.9689 | <0.0001 |
| 2019 | 149 | 3.0405 | 3.0066–3.0745 | |
| 2019 | 149 | 3.0405 | 3.0066–3.0745 | 0.0025 |
| 2020 | 100 | 2.9532 | 2.9063–3.0001 |
* Two-sample T-test.
Dynamics in mosquito weight across years 2016, 2017, 2019, and 2020.
| Year | Samples (N) | Mean Weight | 95% CI | |
|---|---|---|---|---|
| 2016 | 50 | 0.0011 | 0.0010–0.0012 | <0.0001 |
| 2017 | 150 | 0.0016 | 0.0015–0.0017 | |
| 2017 | 150 | 0.0016 | 0.0015–0.0017 | <0.0001 |
| 2019 | 149 | 0.0012 | 0.0012–0.0013 | |
| 2019 | 149 | 0.0012 | 0.0012–0.0013 | 0.4281 |
| 2020 | 100 | 0.0012 | 0.0011–0.0012 |
* Two-sample T-test.